T. Rowe Price Group, Inc. (ETR:TR1)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,059	2,650	2,067	1,756	1,523	2,152
Cash & Short-Term Investments	3,059	2,650	2,067	1,756	1,523	2,152
Cash Growth	12.67%	28.22%	17.71%	15.27%	-29.21%	20.76%
Accounts Receivable	861.8	877.4	807.9	748.7	1,058	863.1
Other Receivables	-	52.4	81	71.2	11.9	25
Receivables	861.8	929.8	888.9	819.9	1,070	888.1
Total Current Assets	3,921	3,580	2,956	2,576	2,593	3,040
Property, Plant & Equipment	1,400	1,204	1,048	1,035	937.4	813
Long-Term Investments	5,349	5,045	4,514	4,143	4,938	5,946
Goodwill	2,643	2,643	2,643	2,643	2,693	665.7
Other Intangible Assets	316.9	368.1	507.3	629.8	913.4	-
Long-Term Deferred Tax Assets	-	278	193.8	216.1	-	60.6
Other Long-Term Assets	712.8	355.2	417.7	401.4	433.4	133.6
Total Assets	14,342	13,472	12,279	11,643	12,509	10,659
Accounts Payable	289.1	292.1	320.1	303.7	317.5	185.2
Accrued Expenses	563.1	219.8	240.8	989.2	1,139	905.8
Short-Term Debt	46.4	59.1	72.3	71.3	75.9	-
Current Portion of Leases	-	31.9	-	-	-	-
Current Income Taxes Payable	22.4	87.1	66.2	46	77.9	85
Other Current Liabilities	-	2.3	13.4	-	-	2.5
Total Current Liabilities	921	692.3	712.8	1,410	1,611	1,179
Long-Term Debt	-	-	17.1	31.7	37.6	-
Long-Term Leases	475.2	246.8	308.5	329.6	249.2	154.1
Other Long-Term Liabilities	1,133	1,083	949.2	184.9	357.8	57.7
Total Liabilities	2,529	2,022	1,988	1,956	2,255	1,390
Common Stock	44	44.6	44.8	44.9	45.8	45.6
Additional Paid-In Capital	99.8	311.9	431.7	437.9	919.8	654.6
Retained Earnings	10,461	10,041	9,076	8,410	8,084	7,030
Comprehensive Income & Other	-44.6	-51.7	-47.5	-53	-26.5	-23
Total Common Equity	10,561	10,345	9,505	8,840	9,023	7,707
Minority Interest	1,252	1,105	786.1	847.4	1,231	1,562
Shareholders' Equity	11,813	11,450	10,291	9,687	10,254	9,269
Total Liabilities & Equity	14,342	13,472	12,279	11,643	12,509	10,659
Total Debt	521.6	337.8	397.9	432.6	362.7	154.1
Net Cash (Debt)	2,537	2,312	1,669	1,323	1,160	1,998
Net Cash Growth	8.51%	38.55%	26.13%	14.01%	-41.91%	22.14%
Net Cash Per Share	11.42	10.35	7.42	5.83	5.07	8.64
Filing Date Shares Outstanding	219.72	222.63	223.66	224.4	228.09	227.95
Total Common Shares Outstanding	219.9	222.97	223.94	224.31	229.18	227.97
Working Capital	3,000	2,887	2,243	1,165	982.6	1,861
Book Value Per Share	48.02	46.40	42.45	39.41	39.37	33.81
Tangible Book Value	7,601	7,335	6,355	5,567	5,416	7,041
Tangible Book Value Per Share	34.56	32.90	28.38	24.82	23.63	30.89
Land	-	25.7	25.7	25.7	25.7	37.2
Buildings	-	493.2	490.7	488.9	472	457.5
Machinery	-	1,906	1,705	1,574	1,499	1,306
Leasehold Improvements	-	414	260.9	236.3	196.4	169.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.